Cargando…
Indacaterol The First Once-daily Long-acting Beta2 Agonist for COPD /
Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are availabl...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Basel :
Springer Basel : Imprint: Springer,
2014.
|
| Edición: | 1st ed. 2014. |
| Colección: | Milestones in Drug Therapy,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-0348-0709-8 | ||
| 003 | DE-He213 | ||
| 005 | 20220117053052.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 131114s2014 sz | s |||| 0|eng d | ||
| 020 | |a 9783034807098 |9 978-3-0348-0709-8 | ||
| 024 | 7 | |a 10.1007/978-3-0348-0709-8 |2 doi | |
| 050 | 4 | |a RM300-666 | |
| 072 | 7 | |a MMG |2 bicssc | |
| 072 | 7 | |a MED071000 |2 bisacsh | |
| 072 | 7 | |a MKG |2 thema | |
| 082 | 0 | 4 | |a 615 |2 23 |
| 245 | 1 | 0 | |a Indacaterol |h [electronic resource] : |b The First Once-daily Long-acting Beta2 Agonist for COPD / |c edited by Alexandre Trifilieff. |
| 250 | |a 1st ed. 2014. | ||
| 264 | 1 | |a Basel : |b Springer Basel : |b Imprint: Springer, |c 2014. | |
| 300 | |a VII, 146 p. 41 illus., 21 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Milestones in Drug Therapy, |x 2296-6064 | |
| 505 | 0 | |a Current Pharmacotherapy for COPD -- The preclinical pharmacology of indacaterol -- The design of the indacaterol molecule -- The early clinical development of Indacaterol -- INHANCE: An adaptive confirmatory study with dose selection at interim -- Phase III clinical efficacy studies - lung function -- Phase III Clinical Efficacy of Indacaterol -- Patient-centered Outcomes -- The history and performance of the Breezhaler device -- What does the future hold for the therapy of COPD? . | |
| 520 | |a Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD. | ||
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Respiratory organs-Diseases. | |
| 650 | 1 | 4 | |a Pharmacology. |
| 650 | 2 | 4 | |a Pneumology. |
| 700 | 1 | |a Trifilieff, Alexandre. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783034807104 |
| 776 | 0 | 8 | |i Printed edition: |z 9783034807081 |
| 830 | 0 | |a Milestones in Drug Therapy, |x 2296-6064 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-0348-0709-8 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||